标签： 最新阿拉上海后花园

Let’s go back to the Baidu AI Developers Conference in 2017.

COO Lu Qi took the lead in making his debut. At 10 o’clock in the morning, he stepped onto the stage on time, occupying the field of vision of 5000 spectators, and blasting a value judgment into the minds of on-site and off-site users:AI will bring mankind into a new era just like the previous three industrial revolutions.

Lu Qi’s voice is firm, powerful and full of confidence, and there is no doubt: "We can definitely lead!"

"AI is an opportunity for Baidu, All In AI."With a wave of his right hand, Lu Qi put his index finger up, calmly "stud" and bet on the whole Baidu.

Luqi

At the end of the meeting, Liu Ji wanting more, announced on the spot:In 2020, Baidu can realize automatic driving of high-speed and urban roads.

Ok, now we can travel back to May 2020. At this time, Lu Qi has left Baidu for two years, and the situation of the artificial intelligence industry has changed greatly.Automatic driving on the high speed is far away.

Wave Computing, a foreign star AI company, laid off its employees and filed for bankruptcy protection. Horizon, a domestic AI head company, was laid off by 50%. At the beginning of this year, the report of Cheetah Global Think Tank showed that the financing amount of AI enterprises experienced a cliff-like decline after 18 years of continuous increase. Compared with 2018, the amount of financing in 2019 decreased from 148.45 billion to 96.727 billion, a decrease of 34.8%, and the amount of financing decreased from 737 to 431, a decrease of 40%.

Since the second half of 2019, IPO plans have been successively spread from Defiance Technology, Shangtang Technology, Yuncong Technology, Excellent Choice and Cambrian. Regrettably, after six months’ application for listing, the status of Defiance was still invalid. Shang Tang was delayed to go public and turned to private equity market for financing. According to the "investment circle" report, Defiance and Shang Tang were frustrated in listing one after another because the valuation was not recognized. CAMBRIAN was asked 20 questions by Shanghai Stock Exchange after applying for listing in science and technology innovation board.

The capital market, which was greeted with smiles before, was completely faceless. Gone are the days when artificial intelligence companies could get high valuations by putting AI tags on PPT two years ago.

At this time, Baidu was caught in a full-scale war with ByteDance. Li Yanhong should have discovered it long ago.All In AI is not an opportunity for Baidu, but a big pit for Baidu.

Today’s situation is particularly clear:The era has emerged, that is, the great migration of content competition from graphic to video. The new traffic generated by this great migration will profoundly affect the entire Internet industry in China. Which big company dominates this great migration will be able to hold the gate of traffic distribution in its own hands, just as Tencent has done in the past 10 years.

Baidu has fallen behind from BAT, which has long been a recognized fact. Today, the market value of Meituan exceeds 100 billion US dollars, and the most unpleasant thing may be Li Yanhong. Although the news of "Baidu delisting" was officially denied, it may not be without reason.

If you want to restore your former glory and re-tie with Erma,The ongoing content ecological war is just one of the few opportunities for Li Yanhong, if not the only one.

Li Yanhong has obviously realized this, so he will vigorously support the live broadcast platform. Baidu executives announced that they will give live broadcast of 10 billion traffic+500 million cash support. However, because it is too late to launch, live broadcast and even the whole short video field, it is already an almost impossible task for Baidu to make a preemptive strike.

If in 2017, before Aauto Quicker and Tik Tok were exposed, Baidu All in was not AI, but content ecology, would the result be different?

The slogan "All in AI" reveals the background color of Lu Qi’s character.

At the end of last year, Lu Qi accepted a late interview and made no secret that he was too confident and was considered "self-righteous" by his wife.

This is Lu Qi’s reflection after he returned to China for three years and suffered setbacks in his two career choices.

But in 2017, ALLINAI-this almost gambling action is undoubtedly a stimulant in front of the lively capital market.

Lu Qi, who put forward this slogan, has been well-known in the Chinese and American science and technology circles for many years, and his resume can’t be picked out-postdoctoral fellow at Carnegie Mellon University, executive vice president of Yahoo and global executive vice president of Microsoft, known as "the most powerful Chinese in Silicon Valley".

It seems that the time has indeed come: in 2016, the "man-machine war"-Alpha Dog defeated Li Shishi in the ninth stage of Go, turned AI, which was originally confined to the fields of science and science fiction, into a popular hot topic on everyone’s lips.

The geographical location has also been created: outside the Fifth Ring Road in Beijing, Lu Qi sat in the Baidu AI conference venue, and the real owner of Baidu, Li Yanhong, performed a stunning scene of unmanned driving outside the Fifth Ring Road. Despite being issued a ticket, compared with the seemingly upcoming driverless era, such a price is completely insignificant.

That night, Baidu’s market value rose by nearly $18 billion.

Half a month later, the State Council released the "New Generation Artificial Intelligence Development Plan", which added another fire to the development of AI at the policy level, and the market quickly detonated. Ma Yun founded the Dharma Institute, Ma Huateng proposed AI in all, and Huawei released the full-stack full-scenario AI strategy. Investors throw money into the wind.

In July of the same year, Shangtang Technology raised $410 million, which was the highest financing record in the world at that time. Three months later, Defiance Technology completed $460 million in financing. At this point, AI Company entered the financing race mode and its records were constantly updated. In May 2018, Shangtang Technology raised $620 million, and Ubisoft completed $820 million. In June, Yunzi raised $1 billion from technology, in July, Shang Tang received $1 billion from Softbank, and in November, Horizon raised $1 billion …

Under the fierce fire, the market soon proved that everyone overestimated the commercial liquidity of AI. At the beginning of 2018, Kai-Fu Lee bluntly said in an interview with China International Television: The bubble of AI will burst. "Every entrepreneur wants to package his startup into an AI company, and every VC wants to flaunt himself as an AI investor. But AI investment is actually not suitable for novices to participate. If you don’t understand the AI ? ? technology itself, you are eager to participate in the early stage of AI, and such people will lose even their pants. "

Baidu’s complex organizational structure casts a shadow over the All in AI strategy.

Lin Ning, a former Baidu cloud worker, said frankly: "Baidu feed stream, driverless and cloud technology all belong to AI, but all departments are running in parallel and are not harmonious with each other."

On the one hand, Li Yanhong led a team to do the familiar and profitable search +feed streaming business, on the other hand, Lu Qi focused on betting on driverless driving.

Both of them are commercialized. Even by 2020, looking at the world, the goal of unmanned commercial mass production is still at the conceptual stage.

Taking Waymo, a driverless company owned by Google, as a reference, Waymo started research and development in 2009, and completed the first phase-10 billion mileage test in 10 years. The mass production stage of the second stage is still stuck.

According to Waymo’s good news at the beginning of this year, it raised 2.25 billion US dollars to produce 80,000 cars. However, according to a survey from the media "high-tech smart car", Waymo’s mass production is unrealistic. Waymo invested more than 5 billion US dollars in research and development in the first ten years. Considering the hardware and software costs of 80,000 vehicles, 2.25 billion US dollars can only be regarded as a drop in the bucket.

Back in the domestic market, the situation of driverless driving is even less optimistic. A Baidu employee told the alphabet list that at present, Baidu’s driverless driving is only used in a limited range. "The domestic landing conditions are immature and the social infrastructure development is not matched, so it is difficult to land on a large scale."

According to Li Deyi, an academician of China Academy of Engineering,Driverless driving will be in the product incubation period before 2025, and mass production is expected to be in 2060.

Driverless driving is difficult to realize, and the profit model of search +feed has already run through, and Li Yanhong’s choice does not need to be guessed at all.

Q1 financial report released in April 2018 shows that revenue increased by 31% year-on-year and net profit was RMB 6.7 billion, up by 277% year-on-year. The unmanned business has no revenue, and search and feed streams have become profit anchors. Asked about the commercialization of AI in the earnings conference call, Lu Qi’s response was vague, and he hoped for the future between the lines.

If you pull the camera back to April 2017 and Lu Qigang joined Baidu’s three-month earnings conference call, his response will be much simpler-face the commercialization of driverless technology raised by analysts and give a clear answer:Realize the commercialization of driverless cars in 2020.

When he joined Baidu in early 2017, Lu Qi shared an experience: jumping on the right boat at the right time. By the late interview at the end of 2019, his quotation added one more sentence: take a step back and broaden the horizon.

In Lin Ning’s view,It is inevitable for Lu Qi to leave Baidu. "Lu Qi chose a track that Baidu is not good at."

Lin Ning said frankly that driverless driving is a very good AI landing scene, and Baidu’s technology is also very good, but the Apollo program is just a famous sound, and the products can’t land at all. "BMW, Mercedes-Benz, Baidu and Apple are all driverless, and what do Internet companies take? Compared with car manufacturers?"

More importantly, this led Baidu to take a fork in the road in strategy and completely fall behind in content layout.

The core of Baidu is search, and the essence of search is content.Baidu tried to rely on AI to make a turnaround, so that it was underinvested and lacked foresight in the main channel of the times-content ecological competition.Throughout 2016, Ali announced the creation of "super consumer media". Tencent has Daily Express and Tencent News to seize the consulting market. The headline is 1 billion, and it is necessary to focus on supporting short videos …

Although Baidu has already made preparations. In 2016, he also laid out 1 billion layouts of 100 numbers. At the media meeting to welcome Lu Qi in January 2017, Li Yanhong emphasized the importance of information flow. "I am confident that users can rely on Baidu to obtain information." In the end, the center of gravity fell on AI. Li Yanhong received a ticket at the Fifth Ring Road, Lu Qi used the Apollo plan to ripen the AI bubble, and the All in AI strategy can be said to be of no help in revenue.

On the other hand, in 2017, advertising revenue reached 15 billion yuan, accumulating hundreds of millions of creators around the world, and hitting the target of 50 billion in 2018. At that time, there were 1 million creators in the same starting point, and the advertising revenue of information flow was less than 10 billion.

In January 2018, before Lu Qi left Baidu, Li Yanhong attended the geek conference, in addition to emphasizing himself.Never said "All in AI"In addition, information flow is specifically mentioned. "Information flow is the focus of Baidu. Most of Baidu’s resources are on Baidu search and Baidu feed stream."

Li yanhong

Looking back now, reassessing Lu Qi’s choice to leave Baidu can be said to be the best of both worlds.

Lu Qi became an investor and joined YC. Later, he founded Miracle, laid out AI consistently and did what he liked.

When Lu Qi left, public opinion fell to the ground and felt sorry for Lu Qi. With data, Baidu couldn’t keep people. In 10 years, he left at least 10 vice presidents and more than 20 executives. Rumors such as internal palace fights and couples seizing power are rampant. Coupled with the bad impression of hemophilia bar and Wei Zexi incident to the public, Baidu was simply sprayed into a sieve.

But I have to say,It is wise for Baidu to loosen the throttle and win Lu Qi in AI strategy, at least it is better late than never.

After Lu Qi left, the voice of Baidu All in AI disappeared. In the Q3 financial report of 2018, the revenue of search and feed stream business accounted for 80% of the total revenue. At the Baidu World Congress held in the same year, the whole package revolved around the content ecology, such as empowering creators, supporting short videos and landing applets, and upgrading Baidu APP into a "comprehensive content consumption and service platform". It also played a tit-for-tat with the headlines, and the frequency of infringement lawsuits by both sides was much higher.

A few days ago, Baidu launched the "Gathering Energy Plan" to supplement the live broadcast business, which can be said to be the foundation of a comprehensive return to the content ecology.

At the same time, the implementation of Baidu’s driverless strategy is obviously more rational. "Driverless gambling is the future, and the return is too far. At present, we can only reduce the research and development costs slowly." A former Baidu employee said.

At the Baidu AI Developers Conference in 2018, Baidu announced the official mass production of the Apollo 3.0 version "Apollon"-"the world’s first L4-class self-driving car". However, compared with Waymo’s mass production of 80,000 vehicles, Baidu’s mass production of "Apollon" is a little shy, with only 100 vehicles. The activity space can only be limited to relatively closed and fixed-line environments such as parks, airports, scenic spots and factories.

Social supervision also needs Baidu to take it slowly. In 2019, Baidu L4 driverless taxis were put into trial production in Changsha. According to national business daily, drivers are on standby at the driver’s position of driverless taxis. These drivers, also known as "security officers", are prepared in accordance with official requirements to ensure the safety of passengers.

According to the unmanned management measures introduced in Shanghai last September, such as vehicles must be equipped with drivers, enterprises must not charge passengers, and must not engage in transportation or business-related activities. This also means that it will take N years for the enterprise’s driverless products to be truly commercialized.

It is not difficult to understand that although Baidu will definitely mention AI in every financial report, people in the industry know that Baidu’s revenue can only rely on content business.

At the end of February this year, the annual financial report with a total revenue of 107.4 billion yuan in 2019 was released, and the search +feed stream sang the leading role. The unmanned appearance only emphasizes business progress, such as cooperating with 23 cities and getting 40 autonomous driving licenses in Beijing. Revenue data has not been disclosed so far.

By May 19th, the latest Q1 financial report with revenue of 22.5 billion yuan and net profit of 3.1 billion yuan, the main force of Baidu’s revenue has not changed, and the financial data of AI business is still missing. The driverless business is completely playing soy sauce in the financial report, and the cloud business has been taken over. The only AI product that is emphasized is only a small one, a smart speaker.

Baidu’s development path in AI strategy is almost the commonality of domestic AI companies.

"Technical improvement is difficult to completely solve the fundamental defects of current AI, which determine that its application space is limited to specific fields-most of them are concentrated in image recognition and speech recognition." This is the conclusion that Zhang Yue, president of Tsinghua University Institute of Artificial Intelligence, accepted in Economic Observer last May.

At the same time, another conclusion of Zhang Yue is that artificial intelligence based on deep learning has technically touched the ceiling.

This seems hard to understand. As far as we can see, AI products appearing on the market, except intelligent robots, face recognition, intelligent customer service and intelligent speakers, have hardly seen products with more advanced technology research and development. Why is the ceiling of AI so low?

However, the reality is in front of us. From the "man-machine war" in 2016, there has been a lot of talk about AI replacing labor. Kai-fu Lee once asserted that 50% of human work will be replaced by AI within 15 years, but four years later, the development process of domestic AI is not optimistic.

At the AI International Conference in June last year, Ma Ziya, Intel’s technical director, said frankly: Emerging technologies such as big data and AI are difficult to land. At present, only 2% of the data is really used to help human production and life.

Back to the AI commercial market. Even in Ali and JD.COM, which have scene advantages, only basic products such as robots and intelligent customer service have been widely used, and more intelligent technologies are still in the conceptual stage.

A typical example is Iflytek, the leading brother in the field of intelligent voice. In September, 2018, I was questioned about "AI simultaneous interpretation fraud". Finally, Liu Qingfeng, the chairman of the board, delivered the hammer himself, claiming that the intelligence level of the current machine could not replace simultaneous interpretation for the time being. By October, CCTV revealed that Iflytek had illegally occupied the Chinese alligator National Nature Reserve in Xuancheng City, Hui Province, and was suspected of using land to build villas under the guise of "AI".

The financing boom that was rolled up like a storm in the past is now flying everywhere.

AI Unicorn Shangtang Technology has raised nearly $3 billion in 9 rounds in 6 years, and its valuation once exceeded $7 billion. Its business covers smart cities, smart phones, pan-cultural entertainment, smart cars, smart health, smart business, education and advertising. Since 2018, it has frequently exposed packaged and sold assets, which has been questioned by observers and has not formed core technical barriers so far.

The company, which competed with Shang Tang for the dominant position in financing, set a new loss record year by year, from a loss of 343 million in 2016 to a direct loss of 5.2 billion in the first half of 2019, and was forced to fall on the road of IPO of Hong Kong stocks.

The Cambrian lost nearly 1.6 billion yuan in three years. In March this year, it submitted an application for IPO in science and technology innovation board, and planned to issue 40.1 million shares, raise at least 2.8 billion yuan, and value itself at 28 billion yuan. Even it was not afraid to show its cards in the prospectus: it could not guarantee profitability in the next few years, and it might face the risk of delisting after listing.

……

Looking back at AI now, the attitude of investors is the most intuitive. Wu Shu, the founder of Qushi Capital, has been paying attention to AI since 2011. He told the alphabet list (ID:wujicaijing): "Many AI directions are promising and valuable, and business models have gradually emerged, butPart of AI was speculated by a group of irrational investment institutions in the early stage, which led to the high valuation deviating from the value, and continued investment became a take-over man. In the end, no one could take it."

Lu Qi, who is also an investor, not only admitted that he was overconfident, but also listed the investment projects he participated in, such as robotics, biotechnology, telecommuting and cloud computing technology.Only there is no unmanned driving.

The last time I responded to the question about driverless driving was in a late interview at the end of last year. When I was asked about the three most optimistic AI landing scenarios, Lu Qi only gave two answers-smart place and new mobile (robot driving).

Facing the reporter’s innuendo on the issue of unmanned driving, Lu Qi said:It is a long process for unmanned driving to completely land in commercialization.

(Lin Ning is a pseudonym)

[Some References]

Dialogue with Lu Qi: It is inevitable to do something long-term and valuable and not be understood, later, December 13, 2019.

"Baidu executives interpret the first quarter financial report, Lu Qi said that it is necessary to strengthen AI innovation", Sina Technology, April 28, 2017;

"Lu Qi: An" outsider "who broke through the fog of Baidu", people, June 28, 2018;

"Shenwang | Baidu’s" new "era after Lu Qi’s curtain call", Shenwang, June 7, 2018.

"Lu qi’s reform is not completed. Baidu returns to the old road? ",Beijing News, May 23, 2018

"Unmanned driving enters the" mass production era "? Dawn at dawn, or a crazy daydream, high-tech smart car, March 8, 2020.

Li Deyi: mass production of driverless cars is expected to be in 2060, China Auto News, May 22, 2019.

"AI Company, Began to Bankruptcy", investment community on May 6, 2020.

"exclusive interview with academician Zhang Wei: deep learning touches the ceiling, and the AI miracle is hard to continue", Economic Observer, May 28, 2019.

Shangtang Technology was exposed to IPO: the listing is uncertain after nine rounds of financing, Blue Whale TMT, March 27, 2020.

All relevant units:

　　The Measures for the Rapid Review and Approval of Medical Devices in Beijing have been deliberated and adopted at the 5th Director’s Office Meeting of Beijing Food and Drug Administration in 2018, and are hereby issued, please follow them.

Beijing Food and Drug Administration

February 9, 2018

Measures of Beijing Municipality for the Examination and Approval of Rapid Review of Medical Devices

　　the first　According to the requirements of the Notice of the General Office of the State Council City, the General Office of the Central Committee of the CPC on Printing and Distributing Opinions on Deepening the Reform of Review and Approval System and Encouraging the Innovation of Medicines and Medical Devices (Z.Z. [2017] No.42), according to the Regulations on the Supervision and Administration of Medical Devices, the Measures for the Administration of the Registration of Medical Devices, the Measures for the Administration of the Registration of In-vitro Diagnostic Reagents and the Policy Matters of the Food and Drug Administration on Supporting the Supervision and Industry Development of Zhongguancun, In order to encourage innovation, encourage the transformation of scientific and technological achievements, improve the efficiency of examination and approval of medical devices in Beijing, and promote the rapid development of medical device industry in Beijing, these measures are formulated.

　　the second　For Beijing medical device products that meet one of the following circumstances, the applicant may apply to Beijing Food and Drug Administration for approval of innovative medical devices:

　　(1) Having relevant national and Beijing scientific research projects, and the patents of core technology inventions involved have been made public or authorized.

　　(2) The invention patent of the core technology, which is the first in Beijing, has the leading product technology in China, has great clinical application value and is involved, has been made public or authorized.

　　(3) Patents for core technology inventions produced by key enterprises in Beijing, such as the 100-thousand-cultivation project and the Beijing Biomedical Industry Leap-forward Development Project (G20), have been made public or authorized.

　　(four) included in the national or Beijing major science and technology projects, key research and development plans;

　　Article　For the implementation of innovative medical devices in accordance with the provisions of Article 2 of these Measures, the person in charge shall be responsible, and early intervention, whole-process counseling, priority registration and testing, priority review and approval, priority registration quality system verification and priority production license matters shall be handled. See Annex 1 for the application requirements of innovative medical devices in Beijing.

　　Article 4　According to the application of the enterprise, Beijing Medical Device Technology Evaluation Center provides pre-consulting services for innovative clinical trial schemes of medical devices that meet the requirements of Article 2 of these Measures.

　　Article 5　For innovative medical devices that meet the requirements of Article 2 of these Measures, enterprises may entrust Beijing medical device manufacturing enterprises to produce products, and the medical device production license of the entrusted party shall obtain the corresponding production scope.

　　Article 6　For innovative medical devices, a cross-disciplinary joint evaluation method can be implemented.

　　Article 7　For innovative medical devices in Beijing that have been listed in the first registration cycle, all adverse medical device events of the product shall be reported and a summary report on monitoring, analysis and evaluation of adverse medical device events shall be submitted to the Beijing medical device adverse event monitoring technical institution and the food and drug administration department in the jurisdiction every year.

　　Article 8　For Beijing medical device products that meet one of the following circumstances, the applicant may apply to Beijing Food and Drug Administration for priority approval of medical devices:

　　(1) It is urgently needed in clinic, and there is no product of the same variety approved for registration in China;

　　(two) the varieties of medical devices belonging to the Beijing medical materials reserve unit and the unique and frequently-occurring diseases of children or disabled people;

　　(3) Diagnosing or treating rare diseases with obvious clinical advantages;

　　(four) for the treatment of serious life-threatening diseases and there is no effective treatment, as well as public health and other urgent needs;

　　(5) Intelligent rehabilitation apparatus;

　　(six) Beijing innovative medical device products to improve the production process.

　　Article 9　For medical device products that meet the requirements of Article 8 of these Measures, priority shall be given to registration and testing, priority shall be given to review and approval, priority shall be given to the verification of registration quality system, and priority shall be given to the handling of production licensing matters. Please refer to Annex 2 for the application requirements for priority approval of medical devices in Beijing.

　　Article 10　For the change of medical device registration license matters, the specification of product name, product technical requirements, scope of application, etc. does not involve substantial content changes, which can be combined with the renewal of registration.

　　Article 11　If the recommended standards, the guiding principles of registration technology review and the norms of registration technology review change in the renewal registration of medical devices, the enterprise may not change the licensing matters.

　　Article 12　If the specifications and models of medical devices are reduced, they can be handled in accordance with the registration procedures.

　　Article 13　For in vitro diagnostic reagent products, it is not necessary to submit analytical performance evaluation data, risk analysis data related to product changes, product technical requirements, product specifications and label samples by increasing the packaging specifications with different loading quantities (only the loading differences) and adding the changes of licensing items for applicable models with the same degree of automation. The time limit for registration review was shortened to 30 working days.

　　On the basis of strictly implementing the requirements of the quality system, the enterprise completes relevant risk analysis, performance evaluation, design changes, etc., and keeps records for future inspection.

　　Article 14　Those who fail to apply for registration renewal six months before the expiration of the validity period shall be registered for the first time. If the product has not changed, the latest registered clinical data, registration test report and system verification results may be submitted.

　　Article 15　Formulate the technical guidelines for clinical evaluation of medical devices in Beijing, study the comparison methods of similar medical devices, and simplify the clinical evaluation data of the same variety of medical devices.

　　Article 16　Beijing Medical Device Technology Evaluation Center has established a communication mechanism for enterprises to solve the difficult problems encountered by enterprises in the registration and evaluation stage of medical devices.

　　Article 17　Integrate the on-site inspection of the registered quality system verification and the on-site inspection of the production license. In principle, after the on-site inspection of the new product registration quality system verification has passed and the medical device registration certificate has been obtained, the products added to the Medical Device Production License can be exempted from the on-site inspection.

　　Article 18　For enterprises that have obtained production licenses, applying for the registration of Class II medical devices that do not involve new methodology or new technology may be exempted from on-site inspection or optimization of on-site inspection items and processes in the process of registration quality system verification.

　　Article 19　If the contents of the change of medical device registration license items do not involve the change of production process, the on-site inspection may be exempted or the on-site inspection items and processes may be optimized in the process of registration quality system verification.

　　Article 20　For those who have passed the on-site inspection of registered quality system verification at least once in two years, and the products applied for inspection this time have the same or similar working principles and expected uses compared with those that have passed the inspection, and have basically the same structural composition, production conditions and production processes, they are exempted from on-site inspection or optimized on-site inspection items and processes in the process of registered quality system verification.

　　Article 21　If the production address is reduced and the production process changes are not involved, the on-site inspection can be exempted or the on-site inspection items and processes can be optimized during the approval of the production license.

　　Article 22　In principle, on-site re-inspection is not required if no key project defects are found in the on-site inspection of the registered quality system, and the number of general project defects accounts for less than 10% of the total number of general projects that should be inspected.

　　Article 23　If the on-site inspection of the production license requires the enterprise to carry out rectification, the enterprise may be required to submit rectification report and rectification data according to the situation of the on-site inspection and the rectification items, and the on-site re-inspection is not required if it can be verified through the data.

　　Article 24　Optimize the registration examination and approval procedures, and cancel the following examination and review links in the administrative examination and approval of medical device registration:

　　(1) First registration of Class II medical device products (including in-vitro diagnostic reagents) that fully implement the guiding principles of product registration technology review issued by china food and drug administration or the product registration technology review norms issued by Beijing Food and Drug Administration;

　　(two) the second class of medical devices (including in vitro diagnostic reagents) continued registration;

　　(three) the second kind of medical devices (excluding in vitro diagnostic reagents) product description changes;

　　(four) the second kind of medical devices (including in vitro diagnostic reagents) product registration certificate error correction.

　　Article 25　These Measures shall not apply to domestic applicants who apply for approval of innovative medical devices to Beijing Food and Drug Administration according to the Notice of the General Administration of Food and Drug Administration on Printing and Distributing Special Approval Procedures for Innovative Medical Devices (Trial) (No.13 [2014] of the Food and Drug Administration).

　　Article 26　These Measures shall be interpreted by the Beijing Food and Drug Administration.

　　Article 27　These Measures shall come into force as of the date of promulgation. The Measures for the Examination and Approval of Medical Devices in Beijing (Trial) issued on August 11, 2016 (Beijing Food and Drug Administration [2016] No.36) was abolished at the same time.

　　Attachment: 1. Requirements for reporting innovative medical devices in Beijing.

　　 　 　 　2. Requirements for priority examination and approval of medical devices in Beijing

Annex 1

Requirements for reporting innovative medical devices in Beijing

　　In order to standardize the application for innovative medical devices in Beijing and improve the quality of application materials, this application requirement is formulated in accordance with the Measures for the Examination and Approval of Rapid Medical Devices in Beijing.

　　I. Application materials for innovative medical devices in Beijing

　　(a) Beijing innovative medical device review application form (Annex 1)

　　The applicant shall truthfully fill in all the contents.

　　The contents filled in the product performance structure and composition, main working principle/action mechanism and expected use should reflect all the important information of product characteristics, be concise and to the point, use standardized and professional terms, and avoid ambiguity.

　　(2) Relevant information of previous applications for innovative medical device approval (approval) (if applicable)

　　If the product has applied for innovative medical device products from china food and drug administration or Beijing Food and Drug Administration, for the innovative medical devices that have been applied for again, copies of previous notices shall be provided, and explanations on product changes and improvement of application materials shall be submitted.

　　(3) A photocopy of the business license of the enterprise to which it applies.

　　(four) the intellectual property rights of the products and the supporting documents.

　　1. Provide a description of the intellectual property rights of the core technology of the innovative medical device applied for. If there are many invention patents, it is suggested to display the information such as the name of the invention patent, the patentee and the patent status in a list.

　　2. Provide relevant intellectual property documents.

　　(1) If the applicant has obtained the patent right for invention, it is required to provide the original copy of the patent power of attorney, the patent claim, the specification and the copy of the patent register signed by the applicant.

　　(2) If the applicant has obtained the right to use the invention patent in China through the transferee according to law, in addition to submitting the copy of the patent authorization, patent claim, specification and patent register held by the patentee, it is also necessary to provide the original Certificate of Filing the Patent License Contract issued by the patent administrative department.

　　(3) If the application for a patent for invention has been made public by the patent administration department of the State Council and is not authorized, it is necessary to provide a copy of the proof document of the publication of the invention patent signed by the applicant (such as the notice of publication of the application for a patent for invention, the notice of publication of the application for a patent for invention and the notice of entry into the substantive examination stage, etc.) and a copy of the published version of the claim and specification. In the process of examining an application for a patent for invention, if the patent claim and specification are modified at the request of the patent examination department, the modified text shall be submitted; Where the patentee changes, the certifying documents issued by the competent patent department, such as a copy of the notice of conformity, shall be submitted.

　　(V) Summary of product development process and results

　　Summarize the original intention of product research and development, laboratory research, animal experimental research, clinical research and results, and submit a comprehensive report on product research and development including design input, design verification and design output. Information on patient selection criteria, as well as parameters to be monitored and factors to be considered during use.

　　(6) Product technical documents, which shall at least include:

　　1. The intended use of the product;

　　(1) It should be made clear that the treatment and diagnosis expected to be provided by the product conform to the purpose defined in Article 76 of the Regulations on the Supervision and Administration of Medical Devices, and the applicable medical stage (such as monitoring and rehabilitation after treatment) can be described;

　　(2) explain whether the product is used once or repeatedly;

　　(3) A description of the equipment expected to be used in combination with it;

　　(4) Information of the target patient population (such as adults, children or newborns).

　　2. Working principle/action mechanism of the product;

　　Elaborate the working principle/mechanism of the product to achieve its expected use, and provide relevant basic research data.

　　3. Make clear the main technical indexes of products and the basis for determination, the index requirements of main raw materials and key components, the main production process and flow chart, and the inspection methods of main technical indexes.

　　(seven) certification documents of product innovation, which shall at least include:

　　1. Novelty retrieval report issued by information or patent retrieval institutions.

　　It should be a sci-tech novelty report issued by information retrieval institutions in China or a novelty report issued by patent retrieval institutions. The contents of the report should be able to prove the innovation point, innovation level and reasons of the product. The novelty retrieval report is valid for one year.

　　2. Summary of academic papers, monographs and documents published in core journals that can fully explain the clinical application value of products (if any)

　　Can provide product literature, but also provide overseas literature of similar products.

　　3. Analysis and comparison of the application of similar products listed at home and abroad.

　　(1) Provide a description of the retrieval of similar products that have been listed in China. Generally, it should include the retrieval database, retrieval date, retrieval keywords and the results retrieved by each keyword, and analyze the differences between the applied innovative medical devices and similar products on the market in terms of working principle/mechanism.

　　(2) Provide an explanation of the application of similar products listed overseas, compare and analyze the similarities and differences with this product, and provide comparative analysis data to support this product to be at the international leading level in technology.

　　4. The innovative content of the product and its remarkable value in clinical application.

　　(1) Overview of innovative medical devices applied for.

　　This paper expounds the innovative contents of the applied medical device, and discusses that the device has been significantly improved in terms of safety, effectiveness and economy compared with the existing products or treatment methods through innovation, and has significant clinical application value.

　　(2) Provide relevant supporting materials.

　　(eight) product safety risk management report.

　　1. Based on the research results of the risk management process carried out by the product.

　　2. Prepared according to YY/T 0316 "Application of Medical Device Risk Management to Medical Devices".

　　(9) Product description (sample draft).

　　It shall comply with the relevant requirements in the Regulations on the Administration of Instructions and Labels of Medical Devices (Order No.6 of the General Administration).

　　(ten) other documents that prove that the product conforms to Article 2 of the Measures for the Examination and Approval of Medical Devices in Beijing.

　　1. If the product or its core technology has won national and Beijing municipal science and technology awards, please explain and submit copies of relevant supporting documents;

　　2. The approval certificate of key supporting enterprises in Beijing, such as the 100 thousand cultivation project and the Beijing biomedical industry leap-forward development project (G20).

　　3 included in the national or Beijing major science and technology projects, key research and development plan documents.

　　(eleven) the self-assurance statement of the authenticity of the submitted materials.

　　Second, the format requirements

　　(a) the application materials shall be compiled by the applicant, and the documents shall be printed on A4 paper, arranged in the order specified in this acceptance requirement and bound into a book.

　　(two) there should be a list of submitted materials, including the first and second titles of the application materials. The data corresponding to each secondary heading shall be separately numbered.

　　(3) Unless otherwise specified, the application materials for the review of innovative medical devices in Beijing shall be original and signed by the applicant. "Signature" refers to the seal of the enterprise, or the signature of its legal representative and responsible person plus the seal of the enterprise.

　　(four) if the application materials are in photocopy, the photocopy shall be clear and consistent with the original. Color pictures and charts shall be provided with color copies. If the original application materials have been submitted in the previous application for examination of innovative medical devices, a copy signed by the applicant can be provided, and the applicant will issue a document stating the acceptance number of the application materials where the original application materials are located.

　　(5) The application materials shall be in Chinese. If the original text is in a foreign language, there should be a Chinese translation.

　　Third, the review process

　　To apply for innovative medical device products in our city, after the above materials are prepared, they shall be reported to the Medical Device Registration and Supervision Department of the Municipal Bureau (hereinafter referred to as the "Device Department"), and the Device Department shall formally review the application materials, and issue a receipt document (Annex 2) within 5 working days; The device will be reviewed by relevant experts within 40 working days, and the applicant and product name will be publicized on the website of Beijing Food and Drug Administration for 10 working days for the varieties to be included in Beijing’s innovative medical devices. If there is no objection after the publicity period, a final review opinion will be issued, and a notice of review of innovative medical devices in Beijing (Annex 3) will be made to inform the applicant in writing.

　　Attachment: 1. Application Form for Review of Innovative Medical Devices in Beijing

　 　 　 　　2. Beijing Innovative Medical Devices Review Receipt Certificate

　 　 　 　　3. Notice of Review Opinions on Innovative Medical Devices in Beijing

Annex 1 of Beijing Municipality’s Declaration Requirements for Innovative Medical Devices

Annex 2 of Beijing Municipality’s Declaration Requirements for Innovative Medical Devices

Beijing Innovative Medical Device Review Receiving Material Voucher

(first copy)

　　(Receiving material number: _ _ _ _ _)

　　：

　　Your company applied for the examination of innovative medical devices in Beijing. After formal examination, the application materials are complete and it is decided to accept it. A total of _ _ pieces of materials were received.

　　Tel: 010-83979525

　　Receiver’s signature: year month day

Beijing Innovative Medical Device Review Receiving Material Voucher

(second copy)

　　(Receiving material number: _ _ _ _ _)

　　：

　　Your company applied for the examination of innovative medical devices in Beijing. After formal examination, the application materials are complete and it is decided to accept it. A total of _ _ pieces of materials were received.

　　Tel: 010-83979525

　　Signature of the applicant: year month day

Annex 3 of Beijing Municipality’s Declaration Requirements for Innovative Medical Devices

Notice of Beijing Municipality on Review Opinions of Innovative Medical Devices

　　(No.:_ _ _ _ _)

　　The application for examination of innovative medical devices in Beijing submitted by your company (receiving material number:)

　　Performance structure and composition:

　　Main working principle/mechanism:

　　The conclusion of the review is:

.

　　I hereby inform you.

(Seal)

Date:

Annex 2

Requirements for Priority Approval and Declaration of Medical Devices in Beijing

　　In order to standardize the application for priority approval of medical devices and improve the quality of application materials, this application requirement is formulated in accordance with the Measures of Beijing Municipality for Rapid Review and Approval of Medical Devices (Revised).

　　First, Beijing gives priority to the examination and approval of medical device application materials.

　　(1) Application Form for Priority Approval of Medical Devices (Annex 1)

　　Clearly explain the circumstances specified in Article 14 of the Measures for the Rapid Review and Approval of Medical Devices in Beijing (Revised), and briefly describe the reasons for priority approval.

　　(two) a copy of the application form for registration of medical devices.

　　(three) in accordance with the "Beijing medical device rapid review and approval measures" eighth cases of medical device priority approval application, should provide information according to the following requirements:

　　1 clinical needs, and there is no product of the same variety approved for registration in China.

　　(1) Summary of the clinical treatment status of the indications of this product, explaining the reasons for urgent clinical need;

　　(2) The overseas approval and clinical use of this product and similar products;

　　(3) Provide a description of the search, which proves that there are no related products of the same variety approved for registration in China at present, and there is no equivalent alternative diagnosis or treatment method at present.

　　2. The medical device reserve varieties belonging to the Beijing medical material reserve unit and the medical device varieties used by children or disabled people with unique and multiple diseases.

　　(1) the certificate of entering the catalogue of medical material reserve units in Beijing;

　　(2) The indication of this product belongs to the supporting data of unique and frequently-occurring diseases of children or disabled people;

　　(3) Summary of the clinical treatment status of this indication;

　　(4) Description and relevant supporting materials proving that the product is specially used for diagnosing or treating unique and frequently-occurring diseases of children or disabled people, and has obvious clinical advantages compared with existing products or treatment methods.

　　3 diagnosis or treatment of rare diseases, and has obvious clinical advantages.

　　(1) Incidence data of the indications of this product and relevant supporting data;

　　(2) Supporting data to prove that the indication is a rare disease;

　　(3) Summary of the clinical treatment status of this indication;

　　(4) Description of the obvious clinical advantages of this product compared with the existing products or treatment methods and relevant supporting materials.

　　4 for the treatment of serious life-threatening diseases and there is no effective treatment, as well as public health and other urgent needs.

　　(1) To prove that the indication belongs to the urgently needed supporting information for treating diseases that are seriously life-threatening and have no effective treatment methods, and public health;

　　(2) Summary of the clinical treatment status of this indication;

　　(3) the product has obvious clinical advantages over the existing products or treatment methods, and relevant supporting materials.

　　5. Intelligent rehabilitation apparatus

　　(1) Medical devices that meet the definition of intelligent rehabilitation devices in the "Thirteenth Five-Year Plan for Scientific and Technological Innovation of Health Industry" (No.149 [2017] of National Science and Technology Development Agency);

　　(2) Summary of the clinical treatment status of this indication;

　　(3) the product has obvious clinical advantages over the existing products or treatment methods, and relevant supporting materials.

　　6. Improve the production process of innovative medical device products in Beijing.

　　(1) Notice of Review Opinions on Innovative Medical Devices in Beijing;

　　(2) Description of production process changes of new and old products.

　　(4) A self-assurance statement on the authenticity of the submitted materials.

　　Second, the format requirements

　　(a) the application materials shall be compiled by the applicant, and the documents shall be printed on A4 paper, arranged in the order specified in this acceptance requirement and bound into a book.

　　(two) there should be a list of submitted materials, including the first and second titles of the application materials. The data corresponding to each secondary heading shall be separately numbered.

　　(3) Unless otherwise specified, the application materials for the examination and approval of priority medical devices in Beijing shall be original and signed by the applicant. "Signature" refers to the seal of the enterprise, or the signature of its legal representative and responsible person plus the seal of the enterprise.

　　(four) if the application materials are in photocopy, the photocopy shall be clear and consistent with the original. Color pictures and charts shall be provided with color copies. If the original application materials have been submitted in the previous priority examination and approval of the medical device application, a copy signed by the applicant can be provided, and the applicant will issue a document stating the acceptance number of the application materials where the original application materials are located.

　　(5) The application materials shall be in Chinese. If the original text is in a foreign language, there should be a Chinese translation.

　　Third, the review process

　　To apply for the priority approval of medical device products in our city, after the above materials are prepared, they shall be reported to the Medical Device Registration and Supervision Department of the Municipal Bureau (hereinafter referred to as the "Device Department"), and the Device Department shall conduct a formal review of the application materials, and issue a receipt document (Annex 2) within 5 working days; The device shall be reviewed by relevant experts within 40 working days, and the applicant and product name shall be publicized on the website of Beijing Food and Drug Administration for 10 working days for the varieties of medical devices to be approved in Beijing. If there is no objection after the publicity period, a final review opinion will be issued, and a notice (Annex 3) for the review of medical devices with priority approval in Beijing will be made, and the applicant will be informed in writing.

　　Attachment: 1. Application Form for Priority Approval of Medical Devices in Beijing

　 　 　 　　2. Beijing Municipality gives priority to the examination and approval of medical devices, and receives the certificate of materials.

　　 　 　 　3. Notice of Beijing Municipality on Priority Examination and Approval of Medical Devices

Annex 1 of the Declaration Requirements for Priority Approval of Medical Devices in Beijing

Annex 2 of the Declaration Requirements for Priority Approval of Medical Devices in Beijing

Beijing Municipality gives priority to the examination and approval of medical devices.

(first copy)

　　(Receiving material number: _ _ _ _ _)

　　：

　　Your company applied for the examination of medical devices with priority approval in Beijing. After formal examination, the application materials are complete and it is decided to accept it. Total materials received　Pieces.

　　Tel: 010-83979525

　　Receiver’s signature: year month day

Beijing Municipality gives priority to the examination and approval of medical devices.

(second copy)

　　(Receiving material number: _ _ _ _ _)

　　：

　　Your company applied for the examination of medical devices with priority approval in Beijing. After formal examination, the application materials are complete and it is decided to accept it. Total materials received　Pieces.

　　Tel: 010-83979525

　　Signature of the applicant: year month day

Annex 3 of the Declaration Requirements for Priority Approval of Medical Devices in Beijing

Notice of Beijing Municipality on Priority Examination and Approval of Medical Devices

　　(No.:_ _ _ _ _)

　　Your application for the examination of medical devices in Beijing with priority approval (receiving material number:)

　　Performance structure and composition:

　　Main working principle/mechanism:

　　The conclusion of the review is:

.

　　I hereby inform you.

(Seal)

Date:

　　[Aika car, domestic new car, original]

　　On August 5th, Trumpchi E9 Champion Edition was officially launched, only one model was launched, priced at 349,800 yuan, the new version is between E9 PRO and E9 MAX, the outer shape adopts the front face of the Oriental lion that is much loved by users, and the interior retains two styles.

　　The Trumpchi E9 Champion Edition has the same shape as the E9 Grandmaster Edition. It adopts a very imposing oriental lion front face design. The huge straight waterfall grille is matched with the sharp Awakening Eye LED headlights on both sides, which are more recognizable. The side shape of the new car is relatively full, and it adopts a large number of flat line designs, combined with the side waist line extending from the front to the tail and the floating roof. The rear "Royal Salute" tail light is matched with a heavy tail design, which makes the whole car look more advanced.

　　In terms of interior, under the two sets of interior styles of Yunshan Zhushui and Opera Palace, a new black top option (only Opera Palace) is added; in terms of configuration, compared with the E9 PRO, the E9 Champion Edition adds a series of comfortable and convenient configuration functions such as one-button SPA, two-row side window sunshades, small table board, and a row of headrests are upgraded to 4-way adjustment, and two-row first-class seats (memory function, electric slide, welcome, and one-click recovery function).

　　In terms of power, the Trumpchi E9 is equipped with a plug-in hybrid system composed of a self-developed 2.0TM hybrid special engine + a 2-speed DHT gearbox and a motor. The system has a comprehensive maximum power of 274kW and a maximum torque of 630Nm. The new car will be equipped with a 25.57kWh battery pack, with a pure electric battery life of 136km under CLTC conditions, and a fuel consumption of 6.05L/100km under WLTC comprehensive conditions, with a comprehensive battery life of 1032km.

　　Editor’s summary: Qi has a position that cannot be ignored in the Chinese MPV market. The cumulative sales of the MPV family (M8 + M6 + E9) have approached 470,000 units, second only to the veteran powerhouse GL8 in the luxury MPV market. Both market share and market reputation are in the top position. The launch of the E9 championship version has also made the team of Trumpchi’s new energy MPV stronger and stronger.

Highlights Review:

Luxury Road Business Class, Test Drive Trumpchi’s New MPV E9

Trumpchi E9’s upward path: not just grandmasters can plug in

GAC Trumpchi E9 officially listed, 32.98-38 9,800 yuan

Special feature of 1905 film network With the students’ party entering the classroom in succession, the "summer file" ended. In the last month of this summer file, in less than 25 days, the overall box office in August has exceeded the 6 billion mark, and finally surpassed February 2016 with a box office of 7.363 billion yuan, creating the latest single-month box office record. As of August 31st, a total of 35 films landed in cinemas in August, among which 31 were domestic films, accounting for 91.80% of the box office.

Wolf Warriors 2, as the first box office list in China at present, naturally became the leader of the box office in August. The fantasy film "The Story of the Shark Pearl", which was made with great production and publicity, was hit by the box office and was full of embarrassment. As the only imported film, Star Agent: City of a Thousand Stars entered the top ten.

　

In the same period, the box office increased greatly, and the cumulative box office broke 40 billion.

As of August 31st, the total box office in August was 7.363 billion, an increase of 81.49% over the same period of last year, a huge increase. Among them, the single-day box office on August 5 reached 527 million yuan, which was the highest in August. On the same day, the attendance rate of Wolf Warriors 2 reached 81.43%, making it the highest in this month. It is worth mentioning that the number of screenings this month is 8.52 million, which is basically the same as last month, but the number of people watching movies has increased by 45%. At the same time, this month, after February this year, the average number of people per show has reached more than 20 again. This is closely related to the high reputation and attendance of films such as Wolf Warriors 2 and Twenty-two.

　　　　　　　　

As of August 31st, the cumulative box office for the whole year has reached 39.583 billion, which is about to exceed 40 billion, an increase of 19.36% compared with the same period of last year. Compared with the time of breaking 40 billion in November last year, it is expected that the target will be reached at least two months ahead of schedule this year.

"Two Wolves" Win More than Half of the Box Office Summer File. The last bus is not easy to take.

A total of 35 films were released this month, including over 100 million domestic films and over 100 million imported films, an overall increase of one from last month. Among the top ten films this month, "Two Wolves" (Wolf Warriors 2 and Kill the Wolf and Greedy Wolf) took 4.7 billion yuan at the box office. A total of four imported films were released in the last week of this month. Except for "Star Agent: City of a Thousand Stars", the other films were relatively eye-catching, and none of them exceeded 200 million in the first weekend of release.

　

　

Although the number of films released in August is still large, except for Wolf Warriors 2, about 30 films only accounted for 38% of the box office. The raging fire of Wolf Warriors 2 burned the whole August, making the box office in a single month even exceed the total box office in March, May and June this year. In the first half of the film’s release, the average attendance rate was as high as 37%, while other films were usually only about 10%. The high-profile films and the high attendance rate, coupled with the patriotic enthusiasm aroused by the Army Day in August, Wolf Warriors 2 just seized this opportunity, so it seems that the high box office of Wolf Warriors 2 is inevitable.

　　　　　　　　

Another film that has been hotly discussed this month is a documentary "Twenty-two". As the first cinema documentary with a box office of over 100 million in China, its achievements and popularity far exceeded expectations. From the time when the film was first released, only 1.5% of the films were arranged, and the box office exceeded 100 million; Under the unfavorable situation that the proportion of films in a single day is only 4.8%, the box office in a single day won 13,537,100 yuan, with an attendance rate of 49.71%. You should know that even Wolf Warriors 2, which ranked first in the box office, only had an attendance rate of 20.78% on that day. "Twenty-two" took it to a box office counterattack with its strong reputation.

　

The two films released on the same day, Psychological Crime and Grand Theft Auto, basically go hand in hand and have similar box office. Another movie, The Legend of the Shark Pearl, which was released on the same day with them, suffered a box office flop, earning 108 million yuan in the first week, while as of the 31st, the movie was released for 21 days, with a box office of only 113 million yuan, indicating that it only earned 5 million yuan in the second two weeks. Although no one expected that "Wolf Warriors 2" would become a "dark horse" at the box office, which affected the box office performance of other films, after all, the audience now watch more blockbusters with top special effects, and the audience can’t be conquered by special effects and scenes alone. Telling a good story is the last word.

　

Star Agent: The City of a Thousand Stars, as the only film to reach the top ten in a month, has occupied the first place in the daily box office list for six consecutive days since its release on the 31st, and the dominance of Wolf Warriors 2 has finally been suppressed, and the box office of 311 million has broken the box office record of luc besson in China. Although the film’s reputation and box office in North America are not good, domestic audiences still buy it, and the special effects alone can be worth the ticket price.

　

The cost of "Jiangxi Huaying" has soared in provinces with box office exceeding 100 million per month.

As of August 31st, the number of effective cinemas nationwide reached 8,455 this month, including 69 new cinemas. In terms of cinemas, Wukesong Store of Beijing Yaolai Jackie Chan International Studios basically took the first place. This month, Shuangjing Store of Beijing UME Studios returned to the top five. It is worth mentioning that Jiangxi Huaying International Cinema ranked ninth and unexpectedly entered the top ten, becoming a "new star" in the rankings almost swept by Beijing and Guangzhou.

However, no matter how the box office situation changes, Wanda Cinema and Guangdong Dadi Cinema always rank first and second in the cinema box office. Compared with last month, only the third and fourth places were reversed, Shenzhen Zhongying Southern Film Shinkansen became the third place, and Shanghai Lianhe Cinema Line slipped to the fourth place.

In terms of regions, due to the high monthly box office this month, the number of provinces with box office exceeding 100 million has increased from about 15 in the past to 24, an increase of 8 compared with July. Among them, Sichuan surpassed Shanghai and Beijing, ranking fourth with 424 million yuan, while Jilin and Guizhou provinces exceeded 100 million yuan for the first time this year.

　

The box office of all cities has increased this month. In August, there were 12 cities with over 100 million yuan nationwide, an increase of 3 from last month. Shanghai topped the list with 411 million yuan, and Beijing was runner-up with 391 million yuan. The total box office of the two cities increased by about 50% compared with last month. Nanjing, Xi ‘an and Dongguan are newly added cities with box office exceeding 100 million this month.

　

Although the box office of Wolf Warriors 2 was bursting this month due to its strong endurance, other films generally performed poorly. Both popular IP and works with small fresh meat or old opera bones were basically reduced to cannon fodder of Wolf Warriors 2 in August. After the craze of Wolf Warriors 2 receded, other films were weak.

　

Nolan’s "Dunkirk" and the film "The Silver Soul" opened the first weekend of September, followed by Hollywood blockbusters for three consecutive weeks. Spider-Man: The Return of Heroes and Rise of the Planet of the Apes 3 will be the highlights that many fans expect in September. As the off-season of box office in September, this year, there are not only "Wolf Warriors 2" postponed to late September, but also many imported blockbusters. This September is worth looking forward to.

Take a look at the new car first, today we will take a look at the ID photos. In the latest batch of MIIT new car catalogs, we found the figure of Dongfeng Yipai S08.

When the brothers heard this name, they must be thinking, Yipai S08? What kind of car is this? In fact, this Yipai S08 is already an old friend in our new car catalog, but its name before was eπ 008, but this time it was changed to Yipai S08.

Looking back at the vehicle itself, this new car is the first model of Dongfeng Yipai, and it is expected to be officially launched in the middle of this year. It is based on Dongfeng Quantum architecture and uses CTC’s technical design scheme, which also makes it more efficient in space utilization.

In addition, in terms of appearance design, this Yipai S08 will feature a simple and atmospheric design style, with a closed front grille and a through-type light strip design, making it look very fashionable.

At the rear of the car, the new car also uses a through-type taillight group, coupled with a spoiler and a black lower surrounding design, which is very visual. However, the reason for the rich vision may be due to the light source in its through-type light group, and the visual effect after lighting will be very good.

In terms of size, the Yipai S08 has a length of 5002mm, a width of 1972mm, a height of 1732mm, and a wheelbase of 3025mm.

Entering the car, the Yipai S08 will feature a similar design to the Yipai 007, featuring an 8.8-inch full-LCD instrument and a 15.6-inch floating central control screen, and a six-seat layout for users to choose from.

In terms of power, Yipai S08 will launch two sets of power system models, pure electric and extended range. The pure electric version will be equipped with a 220kW drive motor and equipped with it. The extended range version will be equipped with a 1.5L engine with an engine power of 108kW and is also equipped, but in this declaration information, the power of the drive motor of the extended range version has not been announced.

Well, this is all the information of Yipai S08. It is said that the future price of this car will be in the range of 20-300,000. How much do you think it will cost after it goes on sale? Come and leave a message in the comment area to discuss with us.

　 　　

　 　 1905 movie network news On August 2, the film (hereinafter referred to as "Concubine Yang") starring Fan Bingbing and Wu Zun made a wonderful appearance at the media conference held in Chengdu, where a production special recording of Fan Bingbing’s shooting process was exposed.

　

　 　 In the special, Fan Bingbing confessed to the shooting process, pouring out that Concubine Yang is not only her lifelong dream as an actress, but also the difference in the script has the power to make people cry. Although Yang Tang’s love has been passed down for thousands of years, Fan Bingbing said that the film aims to create a different spiritual experience for the audience. "In this play, the love between Concubine Yang and Emperor Tang Minghuang should be called significant other souls." In addition, the special exposes the classic scene of "Concubine Yang Drunk". Fan Bingbing said that the shooting experience was very unforgettable to her. In order to truly reflect the contradictions and torn feelings of Concubine Yang, Fan Bingbing boldly chose to change to real wine to make himself drunk during the real shooting.

　

　 　 On the same day, Fan Bingbing was wearing a floral skirt with a slim figure, and many audience members shouted that Fan Bingbing had become thinner. Fan Bingbing said that Wu Zun worked harder for the "concubine". Wu Zun talked about the mood change before and after the filming of the movie, and he said that the movie made him grow a lot. A video of Wu Zun’s daughter neinei cheering for the movie was recently exposed, in which she vowed to be a "little concubine".

　

　 　 The woman of the dynasty, Yang Guifei, was directed by the director Shiqing and completed by Shiqing, Tian Zhuangzhuang and Zhang Yimou, starring Fan Bingbing, Liming, Wu Zun, Wu Gang, Chen Chong and Tranquility. The film was released nationwide on July 30.

On September 1st, Extreme Krypton Intelligent Technology released five core technology evolution achievements at Ningbo International Circuit: Extreme Krypton 001 high-performance version-001fr was officially unveiled; The car is equipped with a four-motor distributed electric drive released in mass production for the first time. The official said that the acceleration of zero hundred is 2.07 seconds; And the torque vector control of the first mass production four wheels is used; Satellite communication technology has also been mass-produced for the first time; In the aspect of energy-supplementing system, extremely charged V3, a charging pile with a single gun peak power of 800kW, has accelerated its evolution.

Source: Extreme official

At the press conference, An Conghui, CEO of Extreme Krypton Intelligent Technology, said: "Extreme Krypton 001 officially launched the push of ZEEKR OS 5.0 version, and the new HMI3.0 was updated and upgraded with interactive experience, landing sentry mode, RSPA remote control direct entry and direct exit parking, door opening warning and many other functions. The extremely high-speed NZP was also officially launched. "

As the pioneer of pure electric hunting coupe, Krypton 001 has a place in the most competitive pure electric market of more than 300,000 by virtue of the value of hunting outfit, the passability of SUV, the space of station wagon and the control of super-running. Based on 001′ s mechanical quality and the product advantage that hunting clothes are all-powerful, extreme krypton 001 evolved to the extreme, and luxury hunting clothes super run 001 FR made its first public appearance.

Extreme Krypton 001 FR turns on the full-stack 800V high-voltage system, which has higher motor output power, stronger charging and discharging ability and higher energy conversion efficiency, matching with 100kWh Kirin battery. According to the official, it only takes 15 minutes to charge from 10% to 80%. At the same time, the four-motor distributed electric drive built by Krypton started mass production, with the performance of 001 FR added, and four high-performance SiC permanent magnet synchronous motors developed by Krypton made its maximum horsepower reach 1265 Ps, and the measured acceleration was 2.36 seconds, excluding the starting time (excluding the starting time: under standard working conditions, excluding the starting time of the first foot). ) Zero-speed acceleration is only 2.07 seconds, and the maximum speed is 280 km/h.

Extreme Krypton 001 FR is a hunting truck that can turn around the tank, and it has a peak torque at the wheel end of over 10,000 Nm. The U-turn of 001 FR tank not only does not pick the road surface, but also can accurately control the direction. Just choose the desired rotation angle, 001 FR can be completed automatically, and the deviation of the center of the circle is less than 20cm when turning around.

On the basis of intelligent drive system, Krypton invented a black technology with pure electrical performance-ZVC Krypton torque vector control. This is the first mass-produced four-wheel torque vector control system, which can monitor the rotating speed of four motors in real time during the whole journey of the vehicle, and accurately distribute and independently control the torque output of each wheel through intelligent algorithms.

Based on ZVC torque vector control, with the 50:50 weight distribution of polar krypton before and after 001 FR, the maximum lateral G value is 1.4 G when 001 FR turns. In addition, in the bottom test of Zhejiang International Circuit, Krypton 001 FR surpassed the fastest mass-produced electric vehicle in the current lap speed list with the fastest lap speed of 1 minute, 37 seconds and 53 seconds, setting a new record for pure electric performance.

More than that, the original factory of Krypton 001 FR has calibrated racing-class high-performance equipment, including Brembo top-class carbon ceramic brake discs, AP track-class ten-piston calipers, KW twisted teeth shock absorbers and other accessories, fully armed high-performance carbon fiber aerodynamic kit and brand-new intelligent driving mode, etc., which will fully stretch the performance of 001 FR. 001 FR is also the world’s first mass production equipped with 8295 intelligent cockpit computing platform. At present, Krypton 001 FR has started booking, with a maximum delivery of 99 units per month. It is expected that the first delivery will be started in late October.

Source: Extreme official

Extreme krypton security re-evolved, and satellite communication technology was put into mass production for the first time in the world. Before the end of the year, 001 FR equipped with vehicle-mounted satellite communication technology will be able to open two-way satellite message and satellite voice call services, and realize sending and receiving messages and satellite calls under the condition of no ground network coverage or damage to the ground network, so as to make travel areas without network signal coverage in the past.

Based on the forward-looking vision of the vast architecture, since the brand was established in 2021, it has adhered to the self-developed, self-built and self-operated ultra-fast charging network. Regardless of scale, performance or core technology, the ultra-fast charging layout of the 800V platform is fully ahead of the industry. As of August 31st, the number of extremely charged stations has reached 348, ranking first in the whole industry, covering 90 cities, with more than 2,000 extremely charged parking spaces.

On the night of the conference, the world’s first extremely charged V3 charging pile was launched, with a single gun with a maximum power of 800kW, a maximum output voltage of 1000V and a maximum output current of 800A, and its core performance set an industry record. By the end of 2023, the V3 will be officially mass-produced, and will be put into use in the first quarter of next year. Extreme Krypton said that the layout of extreme charging is also accelerating. It is estimated that more than 450 extreme charging stations will be completed in 2023. In 2024, it is planned to maintain the speed of "one station a day" and realize the world’s first ultra-fast charging layout under the 800V system.

Starting from September 1st, ZEEKR OS 5.0 officially started pushing. At present, users of Krypton 001 can start OTA upgrade of OS 5.0. These include sentry mode, brand-new HMI3.0, richer cockpit entertainment, more diversified cockpit mode adjustment, and RSPA remote control parking straight in and straight out, door opening warning and other functions. In addition, the OS 5.0 push of Extreme Krypton X is expected to start in September.

In terms of intelligent driving, since the public beta of NZP high-speed autonomous navigation assistance was launched on July 1, the total mileage has exceeded 1.58 million kilometers and the total test time has exceeded 47,000 hours. On September 1st, NZP, an extremely krypton expressway, was officially launched. The first two cities, Shanghai and Hangzhou, were opened, and 17 cities will be opened before the end of the year. The NZP beta of 20 cities will be launched simultaneously before the end of the year.